DK1439830T3 - Farmaceutisk præparat med 2-(4-isobutylphenyl)propionsyre - Google Patents

Farmaceutisk præparat med 2-(4-isobutylphenyl)propionsyre

Info

Publication number
DK1439830T3
DK1439830T3 DK01274674T DK01274674T DK1439830T3 DK 1439830 T3 DK1439830 T3 DK 1439830T3 DK 01274674 T DK01274674 T DK 01274674T DK 01274674 T DK01274674 T DK 01274674T DK 1439830 T3 DK1439830 T3 DK 1439830T3
Authority
DK
Denmark
Prior art keywords
ibuprofen
arginine
isobutylphenyl
propionic acid
pharmaceutical preparation
Prior art date
Application number
DK01274674T
Other languages
Danish (da)
English (en)
Inventor
Leo Pavliv
Original Assignee
Cumberland Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cumberland Pharmaceuticals Inc filed Critical Cumberland Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1439830T3 publication Critical patent/DK1439830T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK01274674T 2001-11-02 2001-11-02 Farmaceutisk præparat med 2-(4-isobutylphenyl)propionsyre DK1439830T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/042894 WO2003039532A1 (en) 2001-11-02 2001-11-02 Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid

Publications (1)

Publication Number Publication Date
DK1439830T3 true DK1439830T3 (da) 2006-02-13

Family

ID=21742977

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01274674T DK1439830T3 (da) 2001-11-02 2001-11-02 Farmaceutisk præparat med 2-(4-isobutylphenyl)propionsyre

Country Status (13)

Country Link
EP (1) EP1439830B1 (ja)
JP (1) JP5185488B2 (ja)
KR (1) KR100851679B1 (ja)
CN (1) CN1302771C (ja)
AT (1) ATE306917T1 (ja)
AU (1) AU2002224475B2 (ja)
CA (1) CA2462452C (ja)
DE (1) DE60114249T2 (ja)
DK (1) DK1439830T3 (ja)
ES (1) ES2253326T3 (ja)
HK (1) HK1068782A1 (ja)
MX (1) MXPA04004024A (ja)
WO (1) WO2003039532A1 (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132823A1 (en) * 2001-11-02 2004-07-08 Leo Pavliv Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
KR101019201B1 (ko) 2008-01-30 2011-03-03 대화제약 주식회사 덱시부프로펜 알지닌염의 제조방법
ES2823249T3 (es) 2009-03-12 2021-05-06 Cumberland Pharmaceuticals Inc Administración de ibuprofeno por vía intravenosa
US8871810B2 (en) * 2009-07-15 2014-10-28 Cumberland Pharmaceuticals Inc. Treating critically ill patients with intravenous ibuprofen
US20110028556A1 (en) * 2009-07-31 2011-02-03 Cumberland Pharmaceuticals, Inc. Treating critically ill patients with intravenous ibuprofen
US8735452B2 (en) * 2009-07-15 2014-05-27 Cumberland Pharmaceuticals Inc. Treating patients with intravenous ibuprofen
MX2010004974A (es) 2010-05-04 2011-11-23 Senosiain S A De C V Lab Combinacion de un aine y un aminoacido.
WO2011144766A1 (es) 2010-05-18 2011-11-24 Spain Pharma, S.A. Composición farmacéutica de ibuprofeno para inyección
PL2635269T3 (pl) 2010-11-04 2019-11-29 Aft Pharmaceuticals Ltd Kompozycja złożona
CN102552117B (zh) * 2010-12-27 2014-07-09 成都天台山制药有限公司 一种含有布洛芬的注射剂及其制备方法
ES2422563B1 (es) * 2012-03-08 2014-06-10 Farmalider S.A. Composición farmacéutica inyectable de ibuprofeno y arginina, su procedimiento de preparación, forma de dosificación unitaria y utilización de la misma
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2014176449A1 (en) * 2013-04-25 2014-10-30 Rinsenergy LLC Oral rinse composition and method to deliver energy supplements
CN103720647A (zh) * 2013-12-16 2014-04-16 扬子江药业集团广州海瑞药业有限公司 一种右旋布洛芬注射液组合物
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
BR112019002058A2 (pt) * 2016-08-02 2019-05-07 Ambah Ip Limited composição injetável de ibuprofeno estável
CN110693822A (zh) * 2019-09-29 2020-01-17 山东罗欣药业集团股份有限公司 一种布洛芬注射液及制备方法
KR20210073905A (ko) 2019-12-11 2021-06-21 (주)휴온스 이부프로펜 및 아르기닌을 함유하는 안정성이 개선된 주사용 제제
US20230172877A1 (en) * 2020-03-11 2023-06-08 University Of Virginia Patent Foundation Metabolites released from apoptotic cells act as novel tissue messengers
KR102478284B1 (ko) 2020-10-28 2022-12-15 이희엽 덱시부프로펜 함유 주사용 액상 조성물
CN112957323B (zh) * 2021-03-29 2022-08-16 北京佳诚医药有限公司 一种右旋布洛芬注射液
KR20220166738A (ko) 2021-06-10 2022-12-19 (주)휴온스 이부프로펜, 아르기닌 및 염화나트륨을 함유하고, 불순물 저감을 통해 안정성이 개선된 희석 주사용 제제
AR127532A1 (es) * 2021-12-01 2024-02-07 Quim Luar S R L Composición farmacéutica que comprende ibuprofeno y arginina

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6393718A (ja) * 1986-10-07 1988-04-25 Green Cross Corp:The 注射剤
DE4010536A1 (de) * 1990-04-02 1991-10-10 Boehringer Mannheim Gmbh Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure
IT1272149B (it) * 1993-03-26 1997-06-11 Zambon Spa Composizione farmeceutiche ad attivita' analgesica
IT1264857B1 (it) * 1993-06-21 1996-10-17 Zambon Spa Composizione farmaceutica liquida per uso orale contenente acido 2-(4-isobutilfenil) propionico

Also Published As

Publication number Publication date
ATE306917T1 (de) 2005-11-15
DE60114249T2 (de) 2006-05-18
HK1068782A1 (en) 2005-05-06
ES2253326T3 (es) 2006-06-01
WO2003039532A1 (en) 2003-05-15
EP1439830A1 (en) 2004-07-28
MXPA04004024A (es) 2004-10-29
CN1302771C (zh) 2007-03-07
DE60114249D1 (de) 2006-03-02
CN1585635A (zh) 2005-02-23
JP2005510510A (ja) 2005-04-21
AU2002224475B2 (en) 2008-01-17
CA2462452C (en) 2006-07-04
CA2462452A1 (en) 2003-05-15
EP1439830B1 (en) 2005-10-19
KR20040063913A (ko) 2004-07-14
JP5185488B2 (ja) 2013-04-17
KR100851679B1 (ko) 2008-08-13

Similar Documents

Publication Publication Date Title
HK1068782A1 (en) Pharmaceutical composition of 2-(4-isobutylphenyl)propionic acid
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
DE50011582D1 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
EA200400777A1 (ru) Фармацевтические композиции соединения платины
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200200059A1 (ru) Комбинация молочнокислых бактерий и ее применение для профилактики и/или лечения инфекций и воспалительных состояний
TR200200649T2 (tr) Farmasötik özelliklere sahip olan yeni aminodikarboksilik asit türevleri
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
MXPA04000891A (es) Nuevos derivados de acido vinilcarboxilico y su uso como antidiabeticos.
PT1098643E (pt) Fenilacetilglutamina fenilacetilisoglutamina e/ou fenilacetato para o tratamento de doencas neoplasicas
HUP0202749A2 (hu) Levoszimendánt tartalmazó oldat formájú gyógyszerkészítmény
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
SE9903831D0 (sv) Formulation of substituted benzimidazoles
DE60313998D1 (de) Schmerzfreie injektions-zubereitungen von 2-arylpropionsäuresalzen
DE60236025D1 (de) Pharmazeutische zusammensetzung enthaltend l-arginin
DE69226447D1 (de) NMDA Antagonisten
NO20052562L (no) Anvendelse av distrontiumsalter av 2-[N,N-di(karboksylmetyl)amino]-3-cyano-4-karboksylmetyl-tiofen-5-karboksylsyre for fremstilling av medikamenter for behandlingen av gastro-duodenal smerte.
KR970706844A (ko) 트롬빈 억제제를 함유하는 저장 안정성 수용액상 주입액(A Storage Stable Water Solution for Infusion Containing A Thrombin Inhibitor)
SE9903611D0 (sv) Novel compounds III
SE0101978D0 (sv) New compounds
EP0030023A3 (en) A heterocyclic compound and its synthesis, pharmaceutical formulations thereof and the use of the compounds and the formulations in medicine
WO2002098843A3 (en) Certain salts of discodermolide acid, pharmaceutical compositions containing them and their use in treating tumors
WO2004093867A3 (en) Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use